文献速递泌尿生殖腹部MRUS

MRI/TRUS融合穿刺与系统穿刺诊断前列腺癌的准确性比较:基于PI-RADS v2的患者内对比研究

MRI/TRUS fusion vs. systematic biopsy: intra-patient comparison of diagnostic accuracy for prostate cancer using PI-RADS v2.
PubMed 文献 · Abdom Radiol (NY) · 2020-01-01

纳入122例疑似前列腺癌且MRI基于PI-RADS v2有可疑发现的患者,于2016年4月至2017年3月间均行MRI/TRUS融合穿刺与系统穿刺。融合穿刺阳性率显著高于系统穿刺(56% vs 48%,p<0.05),在前部病灶中44%仅由融合穿刺检出。结论认为融合穿刺较系统穿刺显著提高前列腺癌检出率,尤其对前部病灶。

要点

  • PI-RADS v2 3、4、5类中临床显著前列腺癌存在率分别为20%、52%、77%(p<0.001)。
  • 融合穿刺阳性率56% vs 系统穿刺48%,差异有统计学意义(p<0.05)。
  • 34例MRI前部病灶中44%仅由融合穿刺检出,联合检出率71%。

诊断标准与关键数值

  • 临床显著病灶定义为Gleason 3+4或更高,83/122例(68%)检出前列腺癌,其中74.6%为临床显著病灶。
  • PI-RADS v2 3、4、5类中临床显著前列腺癌存在率分别为20%、52%、77%(p<0.001)。
  • 融合穿刺阳性患者比例56% vs 系统穿刺48%(p<0.05)。
  • 融合穿刺阳性针芯百分比26% vs 系统穿刺12.3%(p<0.001)。
  • 34例MRI前部病灶中44%仅由融合穿刺检出,联合检出率71%;既往系统穿刺阴性者中48.7%病灶由融合穿刺发现,20.5%仅融合穿刺阳性。

临床应用与阅片要点

  • 作者结论认为融入MRI/TRUS融合穿刺可显著提高前列腺癌检出率,尤其对前部病灶。
  • 单独融合穿刺在20%的患者中为阳性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the efficacy of multiparametric magnetic resonance/transrectal ultrasound fusion (MRI/TRUS fusion) biopsy versus systematic biopsy and its association with PI-RADS v2 categories in patients with suspected prostate cancer.

MATERIALS AND METHODS: 122 patients undergoing both MRI/TRUS fusion and systematic biopsy, with suspicion of prostate cancer, with suspicious findings on MRI based on PI-RADS v2, were included between April 2016 and March 2017. Comparison of tumor detection rates using each technique and combined techniques was performed for all lesions as well as those that are traditionally difficult to access (i.e., anterior lesions).

RESULTS: Prostate cancer was detected in 83/122 patients (68%) with 74.6% clinically significant lesions (Gleason 3 + 4 or greater). There was a statistically significant difference in presence of clinically significant prostate cancer in PI-RADS v2 categories of 3, 4, and 5 (20%, 52% and 77%, respectively, p < 0.001). Fusion biopsy was positive in a significantly higher percentage of patients versus systematic biopsy (56% versus 48%, respectively, p < 0.05). The fusion biopsy alone was positive in 20%. Of 34 patients with anterior lesions on MRI, 44% were detected only by fusion biopsy, with a joint yield of 71%. In patients with previous negative systematic biopsies, 48.7% lesions were found by fusion biopsy with 20.5% being exclusively positive by this method. The percentage of positive cores for fusion biopsies was significantly higher than for systematic biopsies (26% vs. 12.3%, p < 0.001).

CONCLUSION: The incorporation of MRI/TRUS fusion biopsy significantly improves the detection rate of prostate cancer versus systematic biopsy, particularly for anterior lesions.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Labra A, González F, Silva C, et al. MRI/TRUS fusion vs. systematic biopsy: intra-patient comparison of diagnostic accuracy for prostate cancer using PI-RADS v2. Abdom Radiol (NY). 2020. PMID: 32249349. doi:10.1007/s00261-020-02481-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。